192 related articles for article (PubMed ID: 32066910)
1. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
[TBL] [Abstract][Full Text] [Related]
2. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
3. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
[TBL] [Abstract][Full Text] [Related]
4. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
5. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
6. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
[TBL] [Abstract][Full Text] [Related]
7. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
8. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
Bretagne JF; Carlo A; Piette C; Rousseau C; Cosson M; Lièvre A
Br J Cancer; 2021 Nov; 125(11):1494-1502. PubMed ID: 34511603
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
10. Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England.
Benton SC; Piggott C; Blyuss O; Li SJ; Mathews C; Carroll M; Duffy S
J Med Screen; 2021 Dec; 28(4):426-432. PubMed ID: 33983066
[TBL] [Abstract][Full Text] [Related]
11. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
[TBL] [Abstract][Full Text] [Related]
12. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
[TBL] [Abstract][Full Text] [Related]
13. Do faecal test-based colorectal cancer screening pilots provide data that are reflected in subsequent programmes? Evidence from interval cancer proportions.
Clark GR; Steele RJ; Fraser CG
Ann Clin Biochem; 2022 Nov; 59(6):450-452. PubMed ID: 36031942
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
[TBL] [Abstract][Full Text] [Related]
16. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
[TBL] [Abstract][Full Text] [Related]
17. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
[TBL] [Abstract][Full Text] [Related]
18. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
[TBL] [Abstract][Full Text] [Related]
19. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
[TBL] [Abstract][Full Text] [Related]
20. FIT for the future: a case for risk-based colorectal cancer screening using the faecal immunochemical test.
Cooper JA; Moss SM; Smith S; Seaman HE; Taylor-Phillips S; Parsons N; Halloran SP
Colorectal Dis; 2016 Jul; 18(7):650-3. PubMed ID: 27135192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]